Sarah-Jane Dawson

List of Publications by Citations

Source: https://exaly.com/author-pdf/6355800/sarah-jane-dawson-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48 papers	7,741 citations	27 h-index	54 g-index
54 ext. papers	9,640 ext. citations	21.1 avg, IF	5.36 L-index

#	Paper	IF	Citations
48	Analysis of circulating tumor DNA to monitor metastatic breast cancer. *New England Journal of Medicine*, **2013**, 368, 1199-209	59.2	1560
47	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature*, **2013**, 497, 108-12	50.4	1220
46	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. *Science Translational Medicine*, **2012**, 4, 136ra68	17.5	882
45	The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nature Communications*, **2016**, 7, 11479	17.4	779
44	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncology, The*, **2014**, 15, 406-14	21.7	566
43	BET inhibitor resistance emerges from leukaemia stem cells. *Nature*, **2015**, 525, 538-42	50.4	345
42	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. *Nature Communications*, **2015**, 6, 8760	17.4	334
41	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. *New England Journal of Medicine*, **2018**, 378, 1211-1223	59.2	226
40	A new genome-driven integrated classification of breast cancer and its implications. *EMBO Journal*, **2013**, 32, 617-28	13	212
39	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. *Cancer Cell*, **2019**, 36, 385-401.e8	24.3	169
38	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. *Science* , **2020**, 368, 387-394	33.3	146
37	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. *Critical Reviews in Oncology/Hematology*, **2019**, 134, 39-45	7	129
36	Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. *Journal of Clinical Oncology*, **2017**, 35, 1274-1280	2.2	122
35	Non-genetic mechanisms of therapeutic resistance in cancer. *Nature Reviews Cancer*, **2020**, 20, 743-756	31.3	94
34	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. *Nature Medicine*, **2019**, 25, 119-129	50.5	94
33	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". *PLoS Medicine*, **2016**, 13, e1002204	11.6	81
32	Click chemistry enables preclinical evaluation of targeted epigenetic therapies. *Science*, **2017**, 356, 1397-1401	33.9	78

31	Functional interdependence of BRD4 and DOT1L in MLL leukemia. *Nature Structural and Molecular Biology*, **2016**, 23, 673-81	17.6	69
30	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. *Nature Communications*, **2019**, 10, 2723	17.4	67
29	The value of cell-free DNA for molecular pathology. *Journal of Pathology*, **2018**, 244, 616-627	9.4	62
28	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. *Cancer Discovery*, **2019**, 9, 354-369	24.4	60
27	Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. *Journal of Molecular Diagnostics*, **2018**, 20, 883-892	5.1	57
26	HBO1 is required for the maintenance of leukaemia stem cells. *Nature*, **2020**, 577, 266-270	50.4	47
25	A community-based model of rapid autopsy in end-stage cancer patients. *Nature Biotechnology*, **2016**, 34, 1010-1014	44.5	46
24	Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. *Nature Communications*, **2017**, 8, 14756	17.4	44
23	Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. *Blood*, **2017**, 129, 1685-1690	2.2	42
22	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. *Anti-Cancer Drugs*, **2008**, 19, 547-52	2.4	42
21	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.. *JCO Precision Oncology*, **2017**, 1, 1-14	3.6	25
20	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. *Blood*, **2020**, 136, 572-584	2.2	19
19	Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. *Journal of Clinical Oncology*, **2008**, 26, 225-32	2.2	16
18	Multi-omic machine learning predictor of breast cancer therapy response. *Nature*, **2021**,	50.4	15
17	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. *Blood*, **2019**, 134, 756-756	2.2	15
16	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. *Nature Medicine*, **2021**, 27, 1006-1011	50.5	13
15	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. *Diagnostics*, **2021**, 11,	3.8	8
14	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. *PLoS Medicine*, **2020**, 17, e1003363	11.6	7

13	Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. *Journal of Nuclear Medicine*, **2017**, 58, 869-870	8.9	6
12	Characterizing the Cancer Genome in Blood. *Cold Spring Harbor Perspectives in Medicine*, **2019**, 9,	5.4	5
11	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. *Nature Communications*, **2021**, 12, 1434	17.4	5
10	Detection of cell-free microbial DNA using a contaminant-controlled analysis framework. *Genome Biology*, **2021**, 22, 187	18.3	5
9	Combining liquid biopsies and PET-CT for early cancer detection. *Nature Medicine*, **2020**, 26, 1010-1011	50.5	4
8	Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. *Cancer Research*, **2016**, 76, 5590-5591	12.1	4
7	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.. *Oncologist*, **2022**,	5.7	4
6	Large B-cell lymphoma: is the future written in the blood?. *Lancet Oncology, The*, **2015**, 16, 481-3	21.7	3
5	Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma. *Nature Clinical Practice Oncology*, **2006**, 3, 104-7		3
4	Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).. *Journal of Clinical Oncology*, **2018**, 36, 1055-1055	2.2	3
3	Non-genetic determinants of malignant clonal fitness at single-cell resolution. *Nature*, **2021**,	50.4	2
2	Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study		2
1	Liquid biopsies for residual disease and recurrence.. *Med*, **2021**, 2, 1292-1313	31.7	1